RUTI® is the most promising therapeutic vaccine among the dozen projects that are currently being developed in the world. Laboratorios Silanes brings to the agreement their extensive knowledge of the…
Dr Pere-Joan Cardona, inventor of RUTI® vaccine and Scientific Advisor of Archivel Farma, and Olga Rué, company’s CEO, participated in the symposium organized by the TuBerculosis Vaccine Initiative (TBVI), on January…
Archivel Farma, owner of the vaccine, has started a Phase IIa clinical trial to assess the safety and immunogenicity of RUTI® in patients affected by multidrug-resistent tuberculosis (MDR-TB). Dr Pere-Joan…
Archivel has carried out a restructuring of its equipment to facilitate the entry of new partners that can lead the phase III and bring the product to the market. The…
TGT, an industrial group from Barcelona, Spain, has facilitated the exit of the financial investor pool and will inject up to 15M€ over the next four years to help RUTI®…